Ocular Implants Market Report 2025

This Ocular Implants report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The ocular implants market size has grown rapidly in recent years. It will grow from $14.76 billion in 2024 to $16.36 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to ocular trauma, vision correction, diabetic retinopathy, eye diseases, regulatory approvals.

The ocular implants market size is expected to see rapid growth in the next few years. It will grow to $25.32 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to growing aging population, rising myopia prevalence, glaucoma management, minimally invasive surgery, patient safety. Major trends in the forecast period include technological advancements, ophthalmic innovation, digital healthcare, regenerative medicine, digital healthcare, artificial intelligence (ai).

The increase in the global geriatric population is anticipated to drive the growth of the ocular implants market in the future. The geriatric population refers to individuals typically aged 65 and older. Ocular implants offer solutions for common age-related eye conditions such as cataracts, glaucoma, and presbyopia, helping to improve vision, decrease the need for corrective eyewear, and enhance the quality of life for older adults. For example, in October 2022, the World Health Organization, an international public health organization based in Switzerland, projected that the global population of individuals aged 60 years and older would rise to 1.4 billion by 2022, up from 1 billion in 2020. Furthermore, by 2030, it is estimated that 1 in 6 people worldwide will be over 60 years of age. Thus, the growth of the geriatric population globally will stimulate the expansion of the ocular implants market.

The growing prevalence of eye disorders worldwide is expected to significantly drive the growth of the ocular implants market. The most common eye disorders in the U.S. include refractive errors. For example, in 2022, the American Academy of Ophthalmology (AAO) provided statistics on the prevalence of visual impairments related to eye disorders by ethnicity, as well as data on the number of individuals who are legally blind due to these conditions. In the United States alone, approximately 12 million people aged 40 and older experience vision impairment, with about one million suffering from blindness globally. Furthermore, reports indicate that around 2.2 billion individuals worldwide have eye and visual disorders, according to the World Health Organization. Consequently, the rising prevalence of eye disorders, including cataracts and glaucoma, is anticipated to increase the demand for ocular implants.

Major companies in the ocular implants market are concentrating on creating innovative solutions, such as axitinib intravitreal implants, to improve treatment options for eye diseases like retinal vein occlusion and diabetic macular edema. Axitinib intravitreal implants are small, drug-releasing devices inserted directly into the eye’s vitreous cavity to deliver axitinib, a tyrosine kinase inhibitor, in a controlled and sustained manner. For example, Ocular Therapeutix, Inc., a U.S.-based pharmaceutical company, has initiated a pivotal clinical trial for its axitinib intravitreal implant, OTX-TKI, intended for the treatment of wet age-related macular degeneration (wet AMD). This trial aims to evaluate the safety and efficacy of the implant in preserving visual acuity compared to the standard treatment with aflibercept. Designed as a multi-center, randomized study involving approximately 300 patients, the trial seeks to determine the potential of OTX-TKI to provide a sustained release of the drug, which may reduce the frequency of injections needed for effective treatment.

Major companies in the ocular implant market are launching innovative and high-quality iris implant products, such as ARTIFICIALIRIS SELECT, to achieve a competitive edge. ARTIFICIALIRIS SELECT is a premium implant that provides expedited and customizable iris replacement to enhance patient care. For instance, in August 2023, HumanOptics Holding AG, a Germany-based medical technology manufacturer, is set to introduce the premium implant ARTIFICIALIRIS SELECT. This implant offers a variety of color options, including brown, blue, and green, each available in three different shades: light, medium, and dark. Additionally, the implant comes in nine predefined color combinations, ensuring prompt and efficient patient care. Surgeons can easily choose the most suitable color match for the patient by utilizing the specially designed HumanOptics Color Chart SELECT, allowing them to compare it with the patient's healthy eye.

In June 2024, ANI Pharmaceuticals, Inc., a US-based pharmaceutical company, acquired Alimera Sciences, Inc., for an undisclosed sum. This acquisition is intended to strengthen ANI Pharmaceuticals' rare disease segment and ophthalmology portfolio, providing access to two commercially viable assets, Iluvien and Yutiq, which are anticipated to drive substantial revenue growth and enhance ANI's global footprint in the ophthalmology market. Alimera Sciences, Inc., also a US-based pharmaceutical company, specializes in intravitreal (back of the eye) implants.

Major companies operating in the ocular implants market include Alcon Inc., Bausch & Lomb Inc., Carl Zeiss AG, STAAR Surgical Company, Johnson and Johnson Services Inc., Morcher GmbH, Aurolab Ltd., Cornea Biosciences, KERAMED INC., Price Vision Group, Gulden Ophthalmics Co. Inc., AJL Ophthalmic SA, Hoya Corp., Rayner Intraocular Lenses Limited, Lenstec Inc., SIFI S.p.A, Ophtec BV, HumanOptics AG, Medicontur Medical Engineering Ltd., Hanita Lenses, Omni Lens Pvt. Ltd., EyeKon Medical Inc., FCI Ophthalmics Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., AcuFocus Inc., Glaukos Corporation, Ivantis Inc.

North America was the largest region in the ocular implants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ocular implants market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the ocular implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Ocular implants are employed to enhance the vision of individuals. These implants contribute to the restoration of sight in those who have lost an eye due to injury or disease, commonly known as a glass eye, typically crafted from hard plastic acrylic. The prosthetic eye takes the form of a shell, incorporating a clear, artificial lens implant utilized to substitute a clouded natural lens during cataract surgery.

The primary product categories within ocular implants encompass intraocular lenses, corneal implants, orbital implants, glaucoma implants, and others. Intraocular lenses are fashioned from materials such as clear plastic, silicone, or acrylic. These lenses refract light rays entering the eye, facilitating improved vision. Additionally, they are coated with a special material designed to shield the eyes from the harmful ultraviolet rays emitted by the sun. Ocular implants find application in procedures related to glaucoma, diabetic retinopathy, and age-related macular degeneration, and are utilized by end-users such as specialty eye institutes, hospitals, and clinics.

The ocular implants market research report is one of a series of new reports that provides ocular implants market statistics, including ocular implants industry global market size, regional shares, competitors with a ocular implants market share, detailed ocular implants market segments, market trends and opportunities, and any further data you may need to thrive in the ocular implants industry. This ocular implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ocular implants market consists of sales of monofocal lens, toric lens, multifocal and accommodating lenses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.